Lunai Bioworks Inc.

Overview

Compare with Arena Pharmaceuticals, HCW Biologics Inc. or TENAX THERAPEUTICS, INC., or pick any stock.

• TickerLNAI on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersCopenhagen, Denmark²
• Incorporated inDE⁵
• Business addressCentury City Medical Plaza, 2080 Century City East, Suite 906 Los Angeles, Ca 90067⁵
• Filer categoryNon-accelerated filer, Smaller reporting company⁵
• Legal formCorporation²
• LEI5493003O12Q6PNJ56V39²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O Vcorp Services, LLC, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 4928900²

See how the biggest companies compare on our leaderboards

Our ability to continue as a going concern and ability to raise additional capital;⁷ From its latest annual report

Corporate structure

Lunai Bioworks Inc. sits at the top of its group. 7 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lunai Bioworks Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Properties, in its own words

The Company does not currently occupy any material physical office facilities, and our employees primarily work remotely. The Company maintains a virtual office address in Sacramento, California for administrative and corporate purposes. Certain legacy office leases (Century City, California and Boca Raton, Florida) remain outstanding and were in default as of June 30, 2026, and are described in Note 6 to the Financial Statements; although the Company has ceased using the leased premises. We believe that our current remote working arrangements are adequate for our present operations.

Item 2 of the 10-K filed Oct 13, 2026.⁷

Leadership

Who has led Lunai Bioworks Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerDavid Hershel Weinstein Oct 29, 2024 to Oct 29, 2024¹⁷
• Chief executive officerMark Dybul Jul 22, 2021 to Feb 16, 2024¹⁸
• Chief executive officerEric Jean Marie Leire Feb 21, 2014 to Sep 22, 2017¹⁹
• ChairNiels Erik Nielsen Feb 21, 2014 to Feb 21, 2014²⁰
• PresidentEric Jean Marie Leire Feb 21, 2014 to Feb 21, 2014¹⁹
• Chief financial officerNathen Fuentes Jan 13, 2025 to Feb 25, 2025²¹
• Chief financial officerSimon Tarsh Mar 13, 2024 to Nov 6, 2024²²
• Chief financial officerLuisa Puche Feb 28, 2019 to Feb 16, 2024²³
• Chief financial officerLone Degn Jun 8, 2015 to Jun 8, 2015²⁴
• Chief financial officerSasha S. Masri Oct 11, 2011 to Oct 11, 2011²⁵
• Chief operating officerFrancois Binette Feb 16, 2024 to Feb 16, 2024²⁶

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorAvram Miller named Feb 23, 2024⁵²

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• BioSymetrics Corp. Nova Scotia⁶
• BioSymetrics Inc. Delaware⁶
• GEDi Cube Intl Ltd. England and Wales⁶
• Grace Systems B.V. Netherlands⁶
• Lunai Bioworks IP, Inc. Delaware⁶
• Renovaro Biosciences Denmark ApS Denmark⁶
• Renovaro Biosciences, Inc. Delaware⁶

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• RENOVARO INC.Jan 30, 2024 to Aug 26, 2025⁵
• RENOVARO BIOSCIENCES INC.Jun 9, 2023 to Feb 7, 2024⁵
• Enochian Biosciences IncMar 6, 2018 to Aug 1, 2023⁵
• DanDrit Biotech USA, Inc.Feb 14, 2014 to Feb 23, 2018⁵
• Putnam Hills Corp.Aug 12, 2011 to Feb 11, 2014⁵

Timeline

1. Oct 9, 20268-K Other events⁵³
2. Jun 17, 20268-K Other events⁵⁴
3. Jun 16, 20268-K Other events⁵⁵
4. May 20, 20268-K Other events⁵⁶
5. May 13, 20268-K Shareholder vote⁵⁷
6. May 11, 20268-K Listing notice or transfer⁵⁸
7. May 1, 20268-K Entered a material agreement; Completed an acquisition or sale; Listing notice or transfer⁵⁹
8. Apr 28, 20268-K Other events⁶⁰
9. Mar 30, 20268-K Entered a material agreement; Unregistered sale of shares; Other events⁶¹
10. Mar 5, 20268-K Other events⁶²
11. Feb 23, 20268-K Listing notice or transfer⁶³
12. Feb 12, 20268-K Listing notice or transfer; Regulation FD disclosure⁶⁴
13. Oct 29, 2024New chief executive David Hershel Weinstein becomes CEO¹⁷
14. Jul 22, 2021New chief executive Mark Dybul becomes CEO¹⁸
15. Feb 21, 2014New chief executive Eric Jean Marie Leire becomes CEO¹⁹
16. Jan 18, 2011Founded Lunai Bioworks Inc. is founded²

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026⁶⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

336 filings to the SEC since October 2021: 9 annual reports, 18 quarterly reports, 103 major events, 101 insider forms, 42 large holders, 1 private raises, 62 other. The latest 20:

1. Oct 15, 2026SCHEDULE 13D/A EDGAR
2. Oct 13, 202610-K EDGAR
3. Oct 9, 20268-K EDGAR
4. Sep 29, 2026NT 10-K EDGAR
5. Jul 17, 2026SCHEDULE 13G EDGAR
6. Jun 17, 20268-K EDGAR
7. Jun 16, 20268-K EDGAR
8. May 20, 20268-K EDGAR
9. May 15, 202610-Q EDGAR
10. May 13, 20268-K EDGAR
11. May 11, 20268-K/A EDGAR
12. May 1, 2026DEFR14A EDGAR
13. May 1, 20268-K EDGAR
14. Apr 28, 20268-K EDGAR
15. Apr 28, 2026DEFA14A EDGAR
16. Apr 15, 2026DEFR14A EDGAR
17. Apr 13, 2026DEF 14A EDGAR
18. Apr 2, 2026PRE 14A EDGAR
19. Mar 30, 20268-K EDGAR
20. Mar 5, 20268-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

19 open-market trades by officers, directors and large owners since October 2021: 1 buys and 18 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Anderson Wittekind WilliamSCHEDULE 13D/A, 26 filings May 19, 2023 to Oct 15, 2026⁶⁶
• Hans Christian HansenSCHEDULE 13G, 1 filing Jul 17, 2026⁶⁷
• Laksya Ventures Inc.SCHEDULE 13G, 1 filing Sep 26, 2025⁶⁸
• Ole AbildgaardSC 13G/A, 3 filings Oct 6, 2023 to Feb 22, 2024⁶⁹
• Rene SindlevSC 13D/A, 11 filings Jan 24, 2024 to Feb 16, 2024⁷⁰

Money raised

Private offerings the company reported to the SEC on Form D.

1. Feb 13, 2024Raised $106.8 million in a private offering of equity Form D: 8 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Lunai Bioworks Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARLunai Bioworks Inc.¹
• CIK0001527728
• Employer ID (EIN)45-2259340⁷
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁷
• Incorporated inDelaware⁷
• Fiscal year endsJune 30¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressCentury City Medical Plaza, 2080 Century City East, Suite 906 Los Angeles, CA 90067¹
• Phone45 39179840¹
• Shares outstanding5,034,452 shares as of Oct 13, 2026⁷
• Public float$21.3M as of Dec 31, 2025⁷
• AuditorSadler, Gibb & Associates, LLC, Draper, UT PCAOB ID 3627; no auditor attestation of internal control over financial reporting⁷
• On EDGAR sinceAug 12, 2011¹
• Filings593 in all: 8-K (171), 4 (120), 10-Q (45), 3 (38), SC 13D/A (30), UPLOAD (21), DEFA14A (18), CORRESP (16)¹
  All 48 form types

  10-K (14), DEF 14A (9), 10-K/A (8), 8-K/A (8), NT 10-K (8), 4/A (7), NT 10-Q (7), S-1/A (6), SCHEDULE 13D/A (6), EFFECT (4), 10-Q/A (3), 424B3 (3), 424B5 (3), 425 (3), 5 (3), DEFR14A (3), PRE 14A (3), S-3 (3), SC 13D (3), 10-12G/A (2), 144 (2), D (2), DEF 14C (2), S-3/A (2), S-8 (2), SC 13G (2), SC 13G/A (2), SCHEDULE 13G (2), 10-12G (1), 10-KT (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEFM14A (1), PRE 14C (1), PREM14A (1), PRER14A (1), S-1 (1), SC 14F1 (1)

• Latest filingsAnnual report (10-K) Oct 13, 2026
  Quarterly report (10-Q) May 15, 2026
  Proxy statement (DEF 14A) Apr 13, 2026
  Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

From the cover page of the 10-K filed Oct 13, 2026 (Section 12(b) of the Exchange Act).⁷

Risk factors and legal proceedings

The risks Lunai Bioworks Inc. names in Item 1A of its 10-K filed Oct 13, 2026: 58 risks under these headings, as written.⁷

• Risks Related to Our Financial Position and Capital Requirements
• We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future.
• There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
• We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.
• Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.
• From time to time, we may be subject to legal proceedings, regulatory investigations or disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management’s attention, and materially harm our business, financial condition, and operating results.
• Negative publicity has had and may continue to have a negative impact on our business and may have a long-term effect on our relationships with our customers, partners and collaborators.
• Risks Related to Our Limited Operating History
• Lunai Bioworks is a pre-clinical biotechnology company and may never be able to successfully develop marketable products or generate any material product revenue. We have a very limited relevant operating history upon which an evaluation of our performance and prospects can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.
• BioSymetrics is an artificial intelligence (“AI”)-driven healthcare technology company operating in a rapidly evolving field with a limited operating history, which makes it difficult to evaluate its current business and predict future performance.
• BioSymetrics has a history of net losses and anticipates that it may continue to incur net losses for the foreseeable future.
• BioSymetrics’ AI platform and other products may fail to achieve the degree of market acceptance necessary for commercial success.

Legal proceedings

Securities Class Action Litigation. On July 26, 2022 and July 28, 2022, securities class action complaints (the former, the “Chow Action” and the latter, the Manici Action”) were filed by purported stockholders of the Company in the United States District Court for the Central District of California against the Company and certain of the Company’s current and former officers and directors. The complaints allege, among other things, that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact in connection with the Company’s relationship with Serhat Gümrükcü and its commercial prospects. The complaints seek unspecified damages, interest, fees, and costs. On November 22, 2022, the Manici Action was voluntarily dismissed without prejudice. The Chow Action (also referred to as the “Securities Class Action Litigation”) remains pending. On October 22, 2023, the Court appointed a lead plaintiff in the Chow Action. The lead plaintiff filed an amended complaint on December 15, 2023. The Company filed a motion to dismiss the amended complaint on March 15, 2024. The Court denied the Company’s motion to dismiss on June 28, 2024. A mediation was held on September 17, 2024, after which the parties signed a stipulation of settlement. The court granted the lead plaintiff’s motion for preliminary approval of the settlement on August 18, 2025. Plaintiff filed a motion for final approval of the settlement on October 21, 2025. On November 25, 2025, the court held a hearing on lead plaintiff’s motion for final approval of the settlement, and it is currently pending before the court.

The opening of Item 3, Legal Proceedings.⁷